argenex SE $ARGX Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC raised its holdings in shares of argenex SE (NASDAQ:ARGX) by 28.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,503 shares of the company’s stock after purchasing an additional 5,433 shares during the period. Natixis Advisors LLC’s holdings in argenex were worth $18,072,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of ARGX. American Century Companies Inc. increased its position in argenex by 11.6% in the third quarter. American Century Companies Inc. now owns 229,770 shares of the company’s stock worth $169,474,000 after buying an additional 23,864 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of argenex by 91.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock valued at $6,511,000 after acquiring an additional 4,217 shares during the period. Allianz Asset Management GmbH boosted its holdings in shares of argenex by 21.3% during the third quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock valued at $2,708,000 after acquiring an additional 645 shares during the period. Allspring Global Investments Holdings LLC grew its position in shares of argenex by 14.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 211,330 shares of the company’s stock worth $162,160,000 after acquiring an additional 26,343 shares during the last quarter. Finally, US Bancorp DE increased its holdings in shares of argenex by 37.2% in the 3rd quarter. US Bancorp DE now owns 7,073 shares of the company’s stock worth $5,217,000 after acquiring an additional 1,919 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Price Performance

argenex stock opened at $728.09 on Thursday. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62. The stock has a market capitalization of $45.05 billion, a PE ratio of 37.30, a price-to-earnings-growth ratio of 1.23 and a beta of 0.38. The firm has a 50 day simple moving average of $809.43 and a 200-day simple moving average of $816.56.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, February 26th. The company reported $8.02 EPS for the quarter, topping the consensus estimate of $6.05 by $1.97. The firm had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.30 billion. argenex had a return on equity of 38.51% and a net margin of 30.42%. On average, analysts forecast that argenex SE will post 3.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on ARGX. HC Wainwright upped their target price on shares of argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a report on Wednesday, January 21st. Wolfe Research reiterated a “peer perform” rating on shares of argenex in a research report on Monday, November 24th. Citigroup lowered their target price on argenex from $1,124.00 to $1,091.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Finally, Wedbush reaffirmed an “outperform” rating and set a $1,000.00 target price on shares of argenex in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $999.22.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.